ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ENTA Enanta Pharmaceuticals Inc

17.46
0.93 (5.63%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 304,820
Bid Price 16.39
Ask Price 18.00
News -
Day High 17.76

Low
8.08

52 Week Range

High
41.45

Day Low 16.50
Company Name Stock Ticker Symbol Market Type
Enanta Pharmaceuticals Inc ENTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.93 5.63% 17.46 20:00:00
Open Price Low Price High Price Close Price Prev Close
16.71 16.50 17.76 17.46 16.53
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,542 304,820 $ 17.19 $ 5,240,682 - 8.08 - 41.45
Last Trade Time Type Quantity Stock Price Currency
17:12:57 formt 251 $ 17.46 USD

Enanta Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
368.54M 21.16M - 79.2M -133.82M -6.33 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Enanta Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ENTA Message Board. Create One! See More Posts on ENTA Message Board See More Message Board Posts

Historical ENTA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.5017.7613.8615.39374,8442.9620.41%
1 Month14.3517.7613.4715.07252,5233.1121.67%
3 Months10.6017.7610.6013.19275,2006.8664.72%
6 Months11.4217.768.0811.16277,6716.0452.89%
1 Year39.6541.458.0815.65294,382-22.19-55.96%
3 Years49.52102.008.0838.83226,153-32.06-64.74%
5 Years94.47104.038.0845.97206,375-77.01-81.52%

Enanta Pharmaceuticals Description

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Your Recent History

Delayed Upgrade Clock